PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new pill slow kidney damage in IgA nephropathy?
Disease control Not yet recruitingThis study is testing whether an experimental drug called FXS6837 can safely reduce protein in the urine and help preserve kidney function in people with IgA nephropathy, a disease that can lead to kidney failure. About 60 patients who previously completed a shorter study of FXS6…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to reduce kidney damage in IgAN patients
Disease control Not yet recruitingThis study tests an experimental drug called FXS6837 in 60 adults with IgA nephropathy, a kidney disease. Participants will receive either the drug or a placebo for about 6 months. The main goal is to see if the drug lowers protein in the urine, a sign of kidney damage.
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC